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Abstract
Gemtuzumab ozogamicin (GO) is a chemotherapy-conjugated anti-CD33 monoclonal antibody effective in some patients
with acute myeloid leukemia (AML). The optimal treatment schedule and optimal timing of GO administration relative to
other agents remains unknown. Conventional pharmacokinetic analysis has been of limited insight for the schedule
optimization. We developed a mechanism-based mathematical model and employed it to analyze the time-course of free
and GO-bound CD33 molecules on the lekemic blasts in individual AML patients treated with GO. We calculated expected
intravascular drug exposure (I-AUC) as a surrogate marker for the response to the drug. A high CD33 production rate and
low drug efflux were the most important determinants of high I-AUC, characterizing patients with favorable
pharmacokinetic profile and, hence, improved response. I-AUC was insensitive to other studied parameters within
biologically relevant ranges, including internalization rate and dissociation constant. Our computations suggested that even
moderate blast burden reduction prior to drug administration enables lowering of GO doses without significantly
compromising intracellular drug exposure. These findings indicate that GO may optimally be used after cyto-reductive
chemotherapy, rather than before, or concomitantly with it, and that GO efficacy can be maintained by dose reduction to
6 mg/m
2 and a dosing interval of 7 days. Model predictions are validated by comparison with the results of EORTC-GIMEMA
AML19 clinical trial, where two different GO schedules were administered. We suggest that incorporation of our results in
clinical practice can serve identification of the subpopulation of elderly patients who can benefit most of the GO treatment
and enable return of the currently suspended drug to clinic.
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Introduction
Gemtuzumab ozogamicin (GO) is an immunoconjugate be-
tween a humanized IgG4 CD33 monoclonal antibody (mAb) and
a calicheamicin–c1 derivative [1]. The target antigen is expressed
on myeloid cells as well as on leukemic blasts from more than 80%
of AML patients, but is absent on pluripotent hematopoietic stem
cells and non-hematopoietic cells [1]. Binding of GO to the CD33
antigen leads to internalization of the drug-antigen complex and
hydrolytic release of the toxic calicheamicin component [2]. GO
was approved for the treatment of elderly patients with relapsed
AML not considered candidates for standard chemotherapy, after
demonstration of an approximately 25% overall response rate in
this patient population [3]. More recent studies have suggested a
benefit of combining GO with other chemotherapeutics [4], and
ongoing clinical trials are expected to further define the exact role
of GO in AML therapy [5]. However, the optimal schedule and
dosing of GO remains unclear [5]. Recent press-release of the
drug manufacturing company (Pfizer) determined that the drug is
currently withdrawn from the market due to lack of survival
benefit and excessive toxicity in SWOG S0106 randomized
clinical trial where GO was added to the regular induction
treatment in younger AML patient as first line. However,
significant efficacy in elderly patients receiving GO as monother-
apy or with low dose cytotoxics is still debated. Given the
significant toxicities associated with current clinical use of GO,
prospective identification of the patients most likely to benefit from
GO and determination of the most efficacious and least toxic GO
administration schedule is of considerable interest.
Classical population pharmacokinetic (PK) analysis of GO was
performed for the standard dose [6], it showed decrease in volume
of distribution and clearance rate during second drug infusion,
probably due to lowering of the blast burden, which is responsible
for specific CD33 mediated drug clearance. However, this
standard approach failed to provide the information needed for
individualization of the GO dose and administration schedule, as
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Moreover, standard pharmacodynamic analysis of GO is practi-
cally impossible due to requirement for repeated bone marrow
biopsies, which are unethical in average elderly, fragile and ill GO
recipients. Therefore, alternative modelling approaches should be
looked for, allowing for more comprehensive analysis with
relatively few available experimental data. Rational design of
treatment schedules of mAb-based drugs can be accomplished by
mechanism-based models [1,7]. Mathematical models of receptor-
mediated internalization have been developed for peptide ligands
and their receptors [8,9,10,11], and used to analyze target-
mediated drug disposition of non mAb-based drugs [12]. So far,
mechanism-based models have been successfully developed for
unconjugated mAbs [13,14], but not for chemotherapy-conjugat-
ed mAb-based drugs such as GO. Since conjugated mAb-based
drugs are active only upon internalization, the analysis of
intracellular drug content dynamics is important for the overall
evaluation of drug action.
In this work, we present the analysis of a general mechanism-
based model for a conjugated mAb-based drug using experimental
and clinical data of GO interactions with leukemic blasts. The main
objectives of the study were, firstly, to evaluate individual parameter
values of blast-drug interactions in AMLpatients and determination
of their relative significance for the response to treatment, and,
secondly, to propose optimized strategies of GO combined with
other cyto-reductive chemotherapeutics for future clinical trials.
Methods
1. Primary AML blast cell samples
We analyzed by a mathematical model the data from relapsed
AML patients enrolled in the European phase II Mylotarg
protocols 0903B1-202-EU and 0903B1-203-EU, which was
previously obtained and published [2,15,16].
Briefly, peripheral blood was drawn at 0, 3 and 6 hour points
after initiation of a 2-hour intravenous infusion of GO at a dose of
9 mg/m
2. The samples were transferred to the analyzing
laboratory by courier. Peripheral blood cells were then isolated
by density-gradient, and used for analysis of GO binding and
internalization. In addition, density gradient-isolated mononuclear
cells containing leukemic blasts were obtained from pre-treatment
bone marrow specimens to determine drug efflux activity [16].
2. Human AML cell line.
The human AML cell line AML193 was cultured as previously
described [17]. AML193 cells were incubated with various
concentrations of GO, after which CD33 antigen saturation was
evaluated by a flow cytometry assay [2,15].
3. Analysis of GO binding, internalization, and efflux
We carried out parameter estimates of the rate constants of the
mathematical model (see below) using two sets of data, namely in
vitro experiments with the human AML193 cell line as well as
primary AMLblast cells [2,15]. In saturating experiments (performed
on both AML193 cells and patient-derived peripheral blood cells),
cells were incubated at 37uC with a saturating concentration of GO
(5 mg/ml) for different periods of time (0, 1, 3 and 6 hours). In non-
saturating experiments (performed only on AML193 cells), cells were
incubated with different concentrations of GO for 15 minutes at
37uC. After incubation with GO, the amount of membrane-bound
drug and maximal drug binding (the latter representing the total
amount of cell surface CD33 antigen) were assessed by flow
cytometry after incubation with secondary biotinylated anti-human
IgG followed by addition of avidin-FITC [2]. Results were expressed
aschannelvaluesoffluorescence intensity. Inorder totransformthese
values into absolute numbers of fluorescent molecules per cell, the
flow cytometer was calibrated with commercially available FITC-
bearing microbeads (SPHERO
TM Rainbow Calibration Particles,
Spherotech Inc, Lake Forrest, USA). Numbers of fluorescent
molecules per cell were further translated into numbers of CD33
molecules per cell using an appropriate stoichiometric calculation. P-
glycoprotein function was cytofluorometrically assessed by efflux of
the fluorescent P-glycoprotein substrate, DiOC2, and expressed as
mean DiOC2 fluorescence intensity after dye loading divided by
DiOC2 intensity after dye efflux [16].
4. Mechanism-based model of GO-blast interactions
The following mathematical model of mAb-based drug–
leukemic cells interaction was applied to the analysis of the
collected data. We denote by A the concentration of free GO, by
R - the amount of free cell surface CD33 molecules per cell, and
by B - that of drug-bound CD33 molecules per cell. Antibody
binding to CD33 antigen is assumed to be reversible, with
association and dissociation rates kb and ku, respectively. Free
CD33 molecules are assumed to be generated at a constant rate Rp
and to have an internalization rate designated by ke. The rate
coefficient of antibody–antigen complex internalization is denoted
by ki. The model is implemented by the following system of
ordinary differential equations:
dA
dt
~({kb:A:Rzku:B)
N
nA:n
dR
dt
~{kb:A:Rzku:BzRp{ke:R
dB
dt
~kb:A:R{ku:B{ki:B
ð1Þ
N is the number of blast cells, nA is the Avogadro constant and v is
the experimental well volume. Notably, the second and the third
equations describe receptor dynamics on the level of an individual
cell, while the first equation represents the interaction of the whole
leukemic cell population with the drug. The system of equations (1)
was used to model in vitro experiments. The appropriate initial
conditions are: A(0)=A0 (A0, initial drug concentration);
R(0)=Rp/ke; B(0)=0. Here R(0) represents the baseline CD33
antigen expression level (i.e., number of cell surface CD33
molecules before GO administration).
For the experiments with saturating drug dose following modifica-
tions were made to reduce the number of degrees of freedom. If we
denote by T the total number of cell surface CD33 molecules per cell
(T=R+B), then the sum of the last two equations of (1) yields:
dT
dt
~Rp{ke:R{ki:B ð2Þ
Since in saturation experiments R ,, B (bound antigens constitute
more than90% ofthe total,see Figure1A–B) and ke,,ki(i.e., ligand
binding facilitates receptor internalization), then B can be approx-
imated by T and keR term is negligible compared to kiBt e r m .T h u s ,
we obtain:
dT
dt
&Rp{ki:T ð3Þ
The initial condition for equation (3) is T(0)=Rp/ke.
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following system:
dA
dt
~({kb:A:Rzku:B)
N
nA:n
{k:Az
Dose
t:V
dR
dt
~{kb:A:Rzku:BzRp{ke:R
dB
dt
~kb:A:R{ku:B{ki:B
dS
dt
~ki:B{kd:S
N~N0:e{a:t
ð4Þ
The intracellular content of GO and the rate constant of its
elimination by efflux are denoted by S and kd, respectively. We
assume that the leukemic blast number (designated by N) follows
exponential decay, starting 6 hours after the initiation of drug
infusion, therefore N=N0 for t#6. These assumptions are based
on the results of in vitro experiments where AML193 cells were
exposed to GO for different time periods, followed by surviving
fraction measurement [2,15]. N0 is the initial blast number and a
is the rate of blast elimination by the drug. Non-specific drug
elimination rate is designated by k, V is the volume of distribution
as evaluated in the absence of leukemic blasts, and t is the
duration of the drug infusion.
5. Calculation of drug efflux rate
Efflux of GO from leukemic blast cells was previously estimated
using dye efflux [16]. Reported values were ratios of intracellular
dye contents (designated by C) at time 0 and 90 minutes post dye
Figure 1. Estimation of the model parameters from in vitro experiments. Model parameters were estimated by fitting model equations to
the data of in vitro interaction of GO with AML193 cells. AML193 cells were exposed continuously to either saturating GO concentration (5 mg/ml) for
1, 3, and 6 hours, or to non-saturating GO concentrations (0.1 to 0.5 mg/ml) for 15 minutes. In saturating experiments measured amounts of total (A)
and bound (B) CD33 molecules per cell were fitted by equation (3); CD33 production rate (Rp), free (ke) and bound CD33 internalization rates were
estimated. In non-saturating experiments measured amounts of total (C) and bound (D) CD33 molecules per cell were fitted by equations (1);
estimated parameters were drug-CD33 association (kb) and dissociation (ku) rates (Rp,k e and ki were set to their values obtained from the saturating
experiments). Fitting was performed to the results of single representative experiments.
doi:10.1371/journal.pone.0024265.g001
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calculation of efflux rate (kd) can be used:
dC
dt
~{kd:C(t)
kd~
1
t
ln
C(0)
C(t)
 ð5Þ
All computer simulations were run on a PC computer with Matlab
7.0 software using ode23 solver. The model was fitted to mean
data of GO blood concentration time-courses and to individual
data of free and GO-bound CD33 molecules on the peripheral
blasts of GO-treated individual patients using nlinfit routine of
Matlab 7.0.
Results
The model consists of the above presented systems of ordinary
differential equations (1–5) describing in vitro and clinical
experiments. Model parameters include drug-CD33 antigen
association and dissociation rates, CD33 antigen production rate,
rates of free CD33 antigen internalization and CD33 antigen-drug
complex internalization, intracellular drug elimination rate,
non-specific drug elimination rate in blood, blast death rate,
initial blast burden and volume of drug distribution.
1. Evaluation of the model parameters for GO interaction
with leukemic blasts.
1a. In vitro AML cell line experiments. A saturating
concentration of GO (5 mg/ml) was added to cultures of AML193
cells for 1, 3 and 6 hours. The flow cytometry analysis of the cell
populationat thesetime-points allowsquantitative evaluationoftwo
model variables, namely themean number offreecellsurface CD33
molecules and the mean total number of cell surface CD33
molecules. Using these data and equation (3), we estimated rates of
CD33 antigen production, free CD33 antigen internalization and
CD33 antigen-drug complex internalization (Rp,k e, and ki
respectively). The fit of the model simulations to the experimental
measurements is shown in Figure 1.
In separate experiments, AML193 cells were exposed to several
non-saturating GO concentrations for a short time period (15
minutes). Subsequently, the other two model parameters (drug-
CD33 antigen association (kb) and dissociation (ku) rates) were
estimated using the system of equations (1) with the previously
established values for Rp,k e, and ki. The resulting fit of the model
simulations is shown in Figure 1C,D. The values of all the
estimated model parameters are shown in Table 1.
1b. In vitro experiments with patients AML blasts. We
used GO-blast interaction and drug efflux data from phase II trials
of GO monotherapy, [2,15,16] in which blood samples were
drawn 0, 3 and 6 hours after initiation of GO infusion. In order to
be eligible for our analysis, individual patient blood samples had to
have discernable blast population and both peripheral CD33
antigen load and efflux data needed to be available. Forty seven of
276 patients who participated in the trial met these criteria and
were chosen for further analysis.
Since the standard clinical dose of 9 mg/m
2, given as 2 hour
infusion, causes saturation of CD33 antigenic sites during initial
12 hours [6], we used the same procedure applied for the in vitro
saturation experiments to estimate the values for the CD33
production rate as well as free and bound CD33 internalization
rates (Rp,k e, and ki respectively) in individual patients. Non-
saturating experiments were not performed with primary AML
blasts. Consequently, the values of GO-CD33 binding and
dissociation (kb and ku), estimated from in vitro experiments with
AML193 cells, were used for this analysis as well. Drug efflux rates
were calculated from dye efflux ratios [16] using equation (5).
Estimated parameter values are shown in Table 1.
Notably, we did not confine the analysis to measurement of
CD33 expression level (i.e. number of CD33 molecules per cell)
but estimated the two processes determining it – namely CD33
production and internalization separately.
2. Analysis of GO PK in blood and estimation of initial
blast burden
We analyzed the mean blood PK data of GO [6] using our
mechanism-based model. Standard administration of the drug
included two infusions, separated by a 14-day washout period. We
assumed that during the second infusion the number of blasts is
negligible and that the drug is cleared only non-specifically, and
Table 1. Estimates of the model parameters.
Parameter designation and meaning
In vitro data
(AML 193 cell line)
Clinical data
(blast cells from AML patients)
Rp, CD33 production rate (molecules cell
21 hour
21) 2047 279 (109.6)
*
ke, Free CD33 internalization rate (hour
21) 0.12 0.213 (65.7)
ki, GO-CD33 complex internalization rate (hour
21) 0.4 0.66 (50)
kd, GO efflux rate (hour
21) NM 0.34 (64.7)
kb, GO-CD33 association rate (M
21 hour
21) 1.1610
12 NM
ku, GO-CD33 dissociation rate (hour
21) 397.1 NM
k, Non specific drug elimination rate (hour
21) NA 0.01919
N0, Initial total number of blast cells NA 2.47610
12
a, Blast elimination rate (hour
21) NA 0.104
V, Volume of distribution of GO (L) NA 6.2
*results of fitting clinical data are reported as mean, and inter-patient% CV (coefficient of variation)
for those parameters for which estimation in individual patients was possible; NM – not measured;
NA - not applicable; GO – Gemtuzumab Ozogamicin.
doi:10.1371/journal.pone.0024265.t001
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This assumption was based on the fact that in 40% of the AML
patients, the blast count was less than 5% before the second drug
infusion [3], while in most of the remaining 60% of patients,
significant decreases in absolute blast population were noted (VHJ
van der Velden, unpublished data), and our analysis shows that
such a decrease will make the contribution of blast-mediated GO
clearance insignificant (see the explanation below). Figure 2A
shows the fitting curve of the model to the experimental data of the
second drug infusion. The best estimate for the non-specific
elimination rate was 0.01919 (1/hour) and that for the volume of
distribution was 6.2 (liters). Simulation of the model with these
parameter values showed an inadequate fit to the first infusion
during an initial phase, but quite a good fit after 4 days (Figure 2B).
After incorporating specific clearance of the drug by leukemic
blasts (see system of equations (4)), we fitted the model to the first
drug infusion, while varying only the initial number of blasts and
their death rate. The values of non-specific clearance and volume
of distribution were taken from the analysis of the second drug
infusion. All the other parameters were set to population means, as
estimated above (Table 1). The resultant fit of the whole model of
GO blood PK is shown in Figure 2C. The estimated total body
initial number of blasts was 2.47?10
12 cells.
3. Estimation of intracellular exposure to GO and
parameter sensitivity analysis
Significant differences between extracellular and intracellular
GO concentrations could explain a lack of correlation between
area under the curve (AUC) of GO in blood and clinical response.
While direct measurements of intracellular GO concentrations are
currently not feasible since they require repeated bone marrow
biopsies, it is possible to calculate the expected intracellular AUC
(I-AUC) of the drug based on our model parameter estimations.
We used average PK data to perform a sensitivity analysis of
I-AUC to different model parameters. To simulate the model
behavior, we used the system of equations (4) and parameter
values from Table 1. The time series of the simulated blood and
intracellular drug concentrations, together with the mean number
of total and bound cell surface CD33 molecules using mean
parameters values, are shown in Figure 3A,B. The intracellular
drug concentration increased sharply after drug application, and
then decreased to a transient steady state level followed by a slow
decay. To analyze the dependence of I-AUC on different model
parameter, parameter values were changed from one tenth to ten
times their averages, a range that covers the physiologically
relevant values as estimated in individual patients (Table 1). The
results of sensitivity analysis are shown in Figure 4. Initial blast
burden, drug efflux, and the production rate of CD33 antigen
were identified as key parameters influencing I-AUC. A high blast
burden and high efflux were both associated with lower I-AUC, as
expected. Interestingly, the effect of CD33 antigen production on
I-AUC was biphasic: both high and low values of production rate
were associated with low I-AUC. The results of the analysis of
I-AUC sensitivity to CD33 antigen production for a wide range of
initial blast burdens are shown in Figure 5A. Apparently, high
CD33 antigen production caused lower I-AUC only if the initial
blast burden was higher than 5?10
11 (cells/liter). For a blast
burden smaller than 5?10
11, high CD33 production was associated
with increased I-AUC.
We also analyzed the effect of varying the blast burden on
I-AUC for several drug doses. As seen in Figure 5B, I-AUC is
quite insensitive to dose variation above 3 mg/m
2 but sharply
decreases below the 3 mg/m
2 dose.
There was no correlation between the computed values of
I-AUC and AUC obtained by varying 6 of the model parameters
(N0, Dose, kb,R p,k e,o rk i), for a wide range of parameter
combinations (see Figure 6A). Additionally, for the parameter
values found in the studied AML patients, there was no correlation
between I-AUC and CD33 antigen expression level (i.e. number of
CD33 molecules per cell before GO administration) (Figure 6B).
To validate model predictions we analyzed recently published
results of EORTC-GIMEMA AML19 clinical trial, where two
GO administration schedules were compared, in a prospective
randomized fashion: 3 mg/m2 on days 1, 3 and 5 (fractionated
arm), or 6 mg/m2 on day 1 and 3 mg/m2 on day 8. The latter
schedule was found to be more efficacious [18]. Simulations of
these two schedules by our model, using mean population
parameters, demonstrated a lower I-AUC for the fractionated
arm (12,591 mol*day/cell versus 11,075 mol*day/cell). As GO is
active only upon internalization, higher I-AUC may be expected
to result in higher efficacy, as indeed appears in the trial.
Dynamics shown in Fig. 3 provide a plausible explanation for this
result: intracellular GO concentration displays a plateau until day
7, probably due to saturation of the internalization process.
Therefore, additional administration of the drug on days 3 and 5
cannot increase the intracellular drug exposure. Efficacy of the
6 mg/m2 dose in this clinical trial also supports our aforemen-
tioned results that this dose reduction causes only limited decrease
in I-AUC, as compared to the traditional dose of 9 mg/m
2.
Discussion
Three main conclusions can be derived from our analysis. First,
pharmacokinetics of targeted drug delivery by GO can be
accurately modeled using experimental and clinical data on
interactions between GO and AML blast cell. Second, high CD33
antigen production rates and low drug efflux are key factors,
determining high intracellular GO exposure. Third, even a modest
blast burden reduction may increase intracellular GO exposure
and allow the clinical use of a reduced GO dose. Taken together,
the presented mechanism-based PK model for GO may be useful
in prospectively identifying patients that are most likely to benefit
from GO-based therapy, thus improving clinical use of GO.
To the best of our knowledge, this is the first research where
interaction of a monoclonal antibody-based drug with target cell
population was examined in individual patients, assessing PK
parameter sensitivity and its significance for individualizing patient
treatment schedules. Due to the relatively narrow range of the
parameters estimated for different monoclonal antibody-based
drugs [12,13,14], our conclusions on the relative importance of
certain individually-measurable parameters is probably valid for a
wide range of drugs. Therefore, we believe that our approach and
our results have a broad pharmacological, pharmaceutical and
clinical relevance.
We applied a multi-step approach to parameter estimation,
which is better suited for systems with parameters of different
order of magnitude, as is the case here, than grouping together
data taken from experiments of different scales [10]. An AML cell
line was employed to measure the previously unreported drug-
CD33 antigen association and dissociation rates. Since these rates
are determined by chemical processes, they are expected to have
limited inter-individual variability, similar to that of primary AML
cells. In contrast, CD33 antigen production rate, free and bound
CD33 antigen internalization rates, and drug efflux rates, were
estimated individually in primary AML specimens, displaying high
inter-individual variability, which resulted in a wide range of
estimated intracellular exposures to GO.
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influx of GO through CD33 internalization and efflux through P-
glycoprotein. I-AUC is a surrogate for the mean population PD of
GO, assuming that high I-AUC is a prerequisite for a significant
response to the drug [16]. GO internalization constitutes a first
step in the chain of reactions leading to the specific action of
calicheamicin on DNA, but GO processing and its interactions
with DNA are insufficiently studied on a quantitative basis and
cannot be readily assessed in individual patients.
We used previously published data of GO PK in blood for
estimating the volume of distribution, non-specific GO elimination
rate, initial blast burden and blast elimination rate by GO [6]. The
large discrepancy between the estimated volume of distribution
and non-specific drug clearance between the first and the second
drug infusion, produced by a standard compartmental analysis of
GO blood PK, was most likely explained by specific receptor-
mediated drug elimination in leukemic blasts [6]. Therefore, we
incorporated this elimination mechanism in our model under the
assumption of exponentially decreasing numbers of leukemic
blasts. Our adjusted model predictions well retrieved the clinical
results, implying the significance of specific receptor-mediated
drug elimination in the studied process. Moreover, the model-
estimated initial blast burden of 10
12–10
13 cells in AML patients is
similar to that obtained by complex and invasive quantitative
histopathologic and radiometric methods [19,20]. Thus, our
model provides a new non-invasive methodology for evaluating
leukemia burden, by the analysis of individual blood PK data of
conjugated or unconjugated mAb, with a significant receptor-
mediated elimination.
The fact that only mean PK data were available to us posed no
limitation to our study, since one of our major conclusions is that
non-specific drug clearance, peak blood concentration and AUC
are not correlated with the estimated intracellular drug exposure
(Figure 3C). Note that the AUC range evaluated in our study was
5 times larger than the one found in leukemia patients [6].
Previous analyses of clinical GO monotherapy trials show that
many factors determine sensitivity of AML blasts to GO, and
account for the considerable variability of clinical responses [21].
Notably, multi-drug resistance (MDR) mediated by P-glycoprotein
correlated with clinical response but divergent outcomes in AML
patients with low MDR activity, and lack of efficacy of MDR
inhibitors, indicate that additional factors may be of importance
[16]. In a uni-variate analysis, CD33 antigen expression level (i.e.,
the number of cell surface CD33 antigen molecules before drug
administration) was associated with favorable clinical response, but
did not correlate with the response after adjustment for MDR
activity [16]. By comparison, GO-CD33 antigen complex
internalization rate and blood drug AUC showed no correlation
with clinical response [2,6,15]. The latter finding could be
explained by our model simulations. These show that intracellular
drug levels rapidly reach a plateau, which persists for a relatively
long period. In contrast, the free GO concentration in blood
sharply decreases, concluding that there is no correlation between
I-AUC and blood AUC.
Parameter sensitivity analysis showed that three parameters
were critical determinants of I-AUC, namely drug efflux, CD33
antigen production rate, and initial tumor burden, all other
parameters being much less influential. These results are
corroborated by the aforementioned clinical studies [2,6,16]
showing that internalization rate and AUC in blood do not
influence response to GO. It can be stated that the importance of
MDR activity and CD33 production rate on the intracellular
exposure to GO is clear from the drug’s mechanism of action, but
it is impossible to predict that only these two parameters out of nine
possibilities are of major weight without mathematical modeling of
the GO-blast interactions.
Figure 2. Dynamics of concentration of GO in blood during first and second drug infusions. (A) One compartment first order model was
fitted to the free drug concentration in blood during second infusion (data taken from [6]). Estimated parameters were non-specific elimination rate
(k) and volume of distribution (V). (B) The same one compartment model (A) is compared to the data of the drug concentration in blood during first
infusion. (C) The mechanism-based PK model (equations (4)) was used to estimate the initial number of blasts (N0) and their death rate (a) using data
from the first infusion (k and V were set to their values estimated from the data of the second infusion).
doi:10.1371/journal.pone.0024265.g002
Figure 3. Simulation of the of CD33-drug interaction dynamics in patients. The mechanism-based PK model (4) was used to simulate
dynamics of free, cell surface-bound and intracellular drug levels during and after 2-hour intravenous infusion. Model parameter values were set at
population means (Table 1). The time series of each variable is depicted for short (A) and long (B) time period.
doi:10.1371/journal.pone.0024265.g003
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varied, including CD33 production rate (A), association rate (B), initial blast burden (C), internalization rate (D), efflux rate (E), and total drug dose (F).
All the other parameters were kept constant at their mean values (Table 1). I-AUC values were normalized to the value obtained for the set of mean
parameter values. Parameter values are expressed in relative units after normalization to their mean values.
doi:10.1371/journal.pone.0024265.g004
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PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e24265Our model analysis shows that blast burden significantly
influences I-AUC. At low blast burden (less than 5?10
11), I-AUC
was found to be linearly correlated with CD33 antigen production
rate. At high blast burden I-AUC was low, both under high and
under low CD33 antigen production rates. These effects can be
explained by increased blast-mediated specific drug elimination. It is
important to note that our simulations failed to show a correlation of
the CD33 antigen expression levels, per se, with either the estimated
CD33 antigen production rates, or with I-AUC. This is explained by
the fact that CD33 antigen expression levels depend on both CD33
antigen production rate and on free CD33 antigen internalization
rate. These observations are supported by recent studies in
engineered AML cell lines [22]. Significantly, our simulations
demonstrate that by lowering the initial blast burden the I-AUC is
increased. It is, thus, tempting to speculate that reduction of the blast
burden by other chemotherapeutics could improve GO efficacy.
Unfortunately, individualPKdatawerenot available forthe patients
analyzed in our study, and, therefore, individual I-AUCs could not
be computed. Additional clinical trials are required for validating the
proposed use of CD33 antigen production rate, and initial tumor
burden as biomarkers of the response to GO.
The lowest effective GO dose, either as a single agent, or in
combination with other chemotherapeutics, is still unknown. Our
model indicated that increasing the GO dose beyond the standard
9 mg/m
2 [23] does not increase the I-AUC any further, while
decreasing the dose lowers the I-AUC. Nevertheless, for a wide
range of initial blast burdens, the difference in I-AUC between a
dose of 4 or 9 mg/m
2 is less than 20%. Moreover, for a lower blast
burden (less than 5?10
11), GO dose can be further reduced to
3 mg/m
2 with only a 15% decrease in I-AUC.
Figure 5. Effect of blast burden on intracellular exposure to GO. Parameter sensitivity analysis for CD33 production rate (A) and drug dose
(B) was performed for various values of the initial blast burden (total number of blasts in the body). I-AUC and CD33 production rate are expressed in
relative units as in Figure 4.
doi:10.1371/journal.pone.0024265.g005
Figure 6. Lack of correlation between calculated intracellular exposure to GO with AUC of the drug in blood and CD33 expression
level. The mechanism-based PK model (4) was used to simulate dynamics of free, cell surface-bound and intracellular drug levels during and after 2-
hour intravenous infusion. (A) Correlation between blood vs intracellular AUC plot obtained by simulating the mechanism-based PK model and using
wide range of model parameters (N0, Dose, kb,R p,k e,k i set to tenth, one and ten times their average values). (B) Baseline CD33 antigen expression
level vs. calculated intracellular AUC. Each point represents calculation for an individual AML patient. Variable units: AUC – ng/ml*day, I-AUC –
molecules/cell*day, CD33 expression level – molecules/cell.
doi:10.1371/journal.pone.0024265.g006
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PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e24265Our simulation results indicate that the underlying model
appropriately describes GO PK and its interaction with CD33: 1)
the model fits well both blood PK data and the number of free and
bound CD33 molecules on blasts following drug administration; 2)
the estimated mean initial leukemic blast burden is close to
published values [19,20]; and 3) the parameter sensitivity analysis
is congruent with previously published clinical studies.
One limitation of our research was reliance on peripheral blood
blast analysis, rather than on bone marrow data. Since general
conclusions of our analysis are valid for a wide range of
parameters, they probably would not be altered after incorpora-
tion of bone marrow data.
In conclusion, our model predicts that patients who have low
MDR activity and a high CD33 production rates are most likely to
benefit from GO. These two parameters can be evaluated
relatively easily by flow cytometry, after in vitro exposure of blast
cells to GO. Our findings further suggest that GO efficacy could
be enhanced when used after the leukemic tumor burden was
modestly lowered, e.g by alternative cyto-reductive agents. Model
predictions suggest that the second GO dose should not be
administered before day 7, which is corroborated by comparison
with data from prospective randomized trial of GO in elderly
AML patients [18].
We suggest that incorporation of our results in clinical practice
can serve identification of the subpopulation of elderly patients
who can benefit most of the GO treatment and enable return of
the currently suspended drug to clinical armamentarium of
hematologists.
Acknowledgments
We thank Moran Elishmereni for her valuable help in the preparation of
the manuscript.
Author Contributions
Wrote the paper: EJ RBW VHJvdV ZA. Provided all the experimental
data: VHJvdV JGtM RBW. Coordinated and supervised the research: ZA.
Performed mathematical analysis and computer simulations and made the
figures: EJ. Designed the research formulated the mathematical model and
analyzed the data: VV.
References
1. Linenberger ML (2005) CD33-directed therapy with gemtuzumab ozogamicin
in acute myeloid leukemia: progress in understanding cytotoxicity and potential
mechanisms of drug resistance. Leukemia 19: 176–182.
2. van Der Velden VH, te Marvelde JG, Hoogeveen PG, Bernstein ID,
Houtsmuller AB, et al. (2001) Targeting of the CD33-calicheamicin immuno-
conjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro
saturation and internalization by leukemic and normal myeloid cells. Blood 97:
3197–3204.
3. Larson RA, Sievers EL, Stadtmauer EA, Lowenberg B, Estey EH, et al. (2005)
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in
patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer
104: 1442–1452.
4. Burnett AK, Kell WJ, Goldstone AH, Milligan D, Hunter A, Prentice AG, et al.
(2006) The addition of gemtuzumab ozogamicin to induction chemotherapy for
AML improves disease free survival without extra toxicity: preliminary analysis
of 1115 patients in MRC AML15 trial. Blood 108: Abstract 13.
5. Gleissner B, Schlenk R, Bornhauser M, Berdel WE (2007) Gemtuzumab
ozogamicin (mylotarg) for the treatment of acute myeloid leukemia–ongoing
trials. Onkologie 30: 657–662.
6. Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS (2001) Pharmacoki-
netics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent
for the treatment of patients with acute myeloid leukemia in first relapse. J Clin
Pharmacol 41: 1206–1214.
7. Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and
pharmacodynamics. J Pharm Sci 93: 2645–2668.
8. Resat H, Ewald JA, Dixon DA, Wiley HS (2003) An integrated model of
epidermal growth factor receptor trafficking and signal transduction. Biophys J
85: 730–743.
9. Sato H, Sugiyama Y, Tsuji A, Horikoshi I (1996) Importance of receptor-
mediated endocytosis in peptide dekivery and targeting: kinetic aspects. Adv
Drug Del Rev 19(3): 445–467.
10. Tzafriri AR, Wu D, Edelman ER (2004) Analysis of compartmental models of
ligand-induced endocytosis. J Theor Biol 229: 127–138.
11. Wiley HS, Cunningham DD (1981) A steady state model for analyzing the
cellular binding, internalization and degradation of polypeptide ligands. Cell 25:
433–440.
12. Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs
exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn
28: 507–532.
13. Ng CM, Joshi A, Dedrick RL, Garovoy MR, Bauer RJ (2005) Pharmacokinetic-
pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to
severe psoriasis. Pharm Res 22: 1088–1100.
14. Ng CM, Stefanich E, Anand BS, Fielder PJ, Vaickus L (2006) Pharmacokinet-
ics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1)
in healthy human volunteers. Pharm Res 23: 95–103.
15. van der Velden VH, Boeckx N, Jedema I, te Marvelde JG, Hoogeveen PG, et al.
(2004) High CD33-antigen loads in peripheral blood limit the efficacy of
gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia
patients. Leukemia 18: 983–988.
16. Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, et al.
(2007) CD33 expression and P-glycoprotein-mediated drug efflux inversely
correlate and predict clinical outcome in patients with acute myeloid leukemia
treated with gemtuzumab ozogamicin monotherapy. Blood 109: 4168–4170.
17. Jedema I, Barge RM, van der Velden VH, Nijmeijer BA, van Dongen JJ, et al.
(2004) Internalization and cell cycle-dependent killing of leukemic cells by
Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies
with endocytic capacity. Leukemia 18: 316–325.
18. Sergio A, Stefan S, Dominik S, Giuliana A, Liliana B, Vittorio R, et al. (2008)
Phase II-III Study of Gemtuzumab Ozogamicin Monotherapy versus Best
SupportiveCareinOlderPatientswithNewly DiagnosedAMLUnfitforIntensive
Chemotherapy: First Results of the EORTC-GIMEMA AML-19 Trial.
19. Report of the task group on reference man (ICRP 23): anatomical, physiological
and metabolic characteristics: Elsevier(1975).
20. Hiddemann W, Clarkson BD, Buchner T, Melamed MR, Andreeff M (1982)
Bone marrow cell count per cubic millimeter bone marrow: a new parameter for
quantitating therapy-induced cytoreduction in acute leukemia. Blood 59:
216–225.
21. Pagano L, Fianchi L, Caira M, Rutella S, Leone G (2007) The role of
Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.
Oncogene 26: 3679–3690.
22. Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID (2005)
Influence of CD33 expression levels and ITIM-dependent internalization on
gemtuzumab ozogamicin-induced cytotoxicity. Blood 105: 1295–1302.
23. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, et al. (1999)
Selective ablation of acute myeloid leukemia using antibody-targeted chemo-
therapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate.
Blood 93: 3678–3684.
Mechanism-Based PK of Gemtuzumab Ozogamicin
PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e24265